SEC Comment Letter for TARO PHARMACEUTICAL INDUSTRIES LTD (CIK 0000906338) — May 15, 2020
TARO PHARMACEUTICAL INDUSTRIES LTD (CIK 0000906338)
Date: May 15, 2020 · CIK: 0000906338 · Accession: 0000000000-20-004352
AI Filing Summary & Sentiment
File numbers found in text: 001-35463
Letter
United States securities and exchange commission logo May 15, 2020 Daphne Huang Chief Financial Officer TARO PHARMACEUTICAL INDUSTRIES LTD 3 Skyline Drive Hawthorne, New York 10532 Re:TARO PHARMACEUTICAL INDUSTRIES LTD Form 20-F for Fiscal Year Ended March 31, 2019 Filed June 20, 2019 File No. 001-35463 Dear Ms. Huang: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 15, 2020
Daphne Huang
Chief Financial Officer
TARO PHARMACEUTICAL INDUSTRIES LTD
3 Skyline Drive
Hawthorne, New York 10532
Re:TARO PHARMACEUTICAL INDUSTRIES LTD
Form 20-F for Fiscal Year Ended March 31, 2019
Filed June 20, 2019
File No. 001-35463
Dear Ms. Huang:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences